Richard Peters, M.D., Ph.D.
Richard Peters, M.D., Ph.D. has been an active founder, angel investor, and board member of several biotechnology start-ups. Dr. Peters served as Yumanity’s President, Chief Executive Officer and as a member of Yumanity’s board of directors since the completion of the merger of Proteostasis Therapeutics, Inc. and Yumanity, Inc. in December 2020 and has served as the President, Chief Executive Officer and a member of the board of directors of Yumanity, Inc. since September 2019. Previously, Dr. Peters previously served as the President and Chief Executive Officer and a member of the board of directors of Merrimack Pharmaceuticals, a biopharmaceutical company. Dr. Peters also served in various capacities at Sanofi Genzyme, including as Senior Vice President, Head of Global Rare Diseases Business Unit, Vice President, Strategy Development Officer, U.S. Rare Disease Unit, Vice President, Division Medical Officer, Global Oncology Division, and Vice President, Head of Global and U.S. Medical Affairs, Hematology and Transplant. Prior to Sanofi Genzyme, Dr. Peters held medical affairs roles at Onyx Pharmaceuticals, Inc. and Amgen Inc. and was a co-founder and Chief Executive Officer of Mednav, Inc., a private 379 healthcare information technology company. Dr. Peters serves as Chairman of the board of directors of Aprea Therapeutics, Inc. as well as Chair of the compensation committee. Dr. Peters has also served on the faculty at Harvard Medical School/Massachusetts General Hospital.
Dr. Peters holds a B.S. from the College of Charleston and an M.D. and a Ph.D. in Pharmacology from the Medical University of South Carolina.